 |
 |
|
Nissan Chemical entered into the pharmaceutical
business in 1982, and introduced an external
preparation, ketoprofen (EPATEC®) in
1985.
In 1994, efonidipine hydrochloride (LANDEL®), a
Ca antagonist was launched as our company's
first new pharmaceuticals for the indication
of hypertension. It was added renoparenchymal
hypertension and angina pectoris as its indications
in 1998. In South Korea, efonidipine
hydrochloride (FINTE®) was also introduced
in 2003.
Pitavastatin calcium (LIVALO®), a
statin agent with a strong LDL cholesterol
reduction, for the indication of hyperlipidemia
was marketed in Japan in 2003. LIVALO®
was also introduced to South Korea in 2005,
to Thailand in 2008 and to China in
2009. It has been approved in the United
States in 2009, and applied for approval
in Europe.
Concerning the new drug development
pipelines, a therapeutic agent for peripheral
arterial disease (NM/NT/INDI-702) is in the
process of clinical development in Japan
and in the United States. The clinical
development with a therapeutic and preventive
drug for atrial fibrillation and flutter
(NTC-801) has been started in 2007.
Further, the clinical development with a
new therapeutic agent for thrombocytopenia
(NIP-022) has been started in the United
States in 2009.
Nissan Chemical keeps trying research and
development for innovative medicines by using
the strategic chemical library, the state-of-the-art
evaluation technology and precise organic
synthesis technology. |
|
|
 PHARMACEUTICAL AGENTS
|
|
|
|
| [ LIVALO® ] |
|
| LIVALO® is a statin agent with a strong
LDL cholesterol reduction, which causes less
drug-interactions. It is manufactured
and distributed by Kowa Company, Ltd., and
distributed by Kowa Pharmaceutical Co. Ltd.
and Daiichi Sankyo Co., Ltd. in Japan. In
South Korea, it is licensed to Choongwae
Pharma Corporation. This agent is recognized
as one of the new-generation of statins,
"Strong statins" in clinical practice.
It is also introduced to Asian countries,
such as South Korea, Thailand and China.
It has been approved in the United
States in 2009. Further, it has been
applied for approval in Europe and prepared
for application in Canada. It is developed
in the other areas (Taiwan, Indonesia, etc.) |
|
|
 |
|
| [ LANDEL® ] |
|
| LANDEL® is a dual type Ca antagonist
that blocks not only L-type calcium channels
but also T-type ones. It is distributed
by Zeria Pharmaceutical Co., Ltd. and Shionogi
& Co., Ltd. in Japan. This agent
shows beneficial effects on hypertension
and angina pectoris. In addition, the
agent is expected to show a renal protective
and a cardioprotective effects. |
|
|
|
|
| [ EPATEC® ] |
|
| EPATEC® is an antiphlogistic analgetic
for external use (gel, cream and lotion),
which contains the active ingredient ketoprofen.
This agent has been succeeded by Zeria
Pharmaceutical Co., Ltd. in April 2008. |
|
|
|
|
 New Medicines under Development |
| [ NT/NM/INDI-702 ] |
|
| This agent has both a phosphodiesterase inhibitory
effect and a thromboxane A2 synthetase inhibitory effect, and is under
development with Taisho Pharmaceutical Co.,
Ltd. in Japan. Clinical trials not
only for intermittent claudication associated
with peripheral arterial disease but also
asthma are under way. We have entered
a license agreement with Indigo Pharmaceuticals,
Inc. (INDIGO), and have granted INDIGO exclusive
development and marketing rights worldwide,
except in Japan, South Korea, China and Taiwan.
INDIGO prepares to begin Phase III
clinical trials for intermittent claudication. |
|
|
|
|
| [ NTC-801 ] |
|
| NTC-801 is a new antiarrhythmic agent that
inhibits the acetylcholine-activated pottasium
channel current (IKACh). Because IKACh channel
is apparent in the atrium but not in the
ventricle, NTC-801 has the potential to be
an atrial selective agent for the treatment
of atrial fibrillation. In Japan, NTC-801 is
currently under Phase II clinical trial with
Teijin Pharma Limited. Outside of Japan,
we have executed a licensing agreement with
Bristol-Myers Squibb Company, and have granted
Bristol-Myers Squibb exclusive development
and marketing rights worldwide, except in
Japan. |
|
|
|
| [ NIP-022] |
|
| NIP-022 is an orally active agent which
may increase platelet count by activating
a receptor of thrombopoietin. We and
Ono Pharmaceuticals Co. Ltd. (Ono) entered
into a license agreement in December 2007,
and are jointly developing the agent worldwide.
Phase I clinical trial is conducted
in the United States by Ono (Ono's development
code: ONO-7746). |
|
|
|
|
|
IR Library
